Lilly received a higher Jefferies target, a Canadian coverage recommendation for Kisunla, and positive Foundayo trial results. Its overseas patient opportunity and 63% U.S. share support its outlook, though Foundayo still needs a U.S. filing.
The new information points to more ways for Lilly to sell its medicines. Jefferies sees an overseas GLP-1 patient group about twice the U.S. size, and Lilly has a 63% U.S. share. Canada's coverage recommendation and Foundayo's trial results add support. Foundayo still needs a U.S. filing, and Jefferies' target is an analyst's opinion, not a company promise.
Novo's rival Lilly has about 63% of the U.S. GLP-1 market, and Novo has faced setbacks, including mixed pipeline data. These facts point to pressure on Novo's position.
Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLY